In this scenario, it is worth mentioning that inhibition of PCSK9 (evolocumab) is being tested in metastatic pancreatic cancer (NCT-04862260) and glioblastoma (NCT-04937413). This evidence concerns the gene PCSK9 and glioblastoma.